> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Meeting Set for Schizophrenia Trial Considerations
- URL: https://www.fdaweb.com/meeting-set-for-schizophrenia-trial-considerations/
- Published: 2024-05-03T12:00:00.000Z
- Updated: 2026-09-14T14:29:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156915

FDA has announced an 8/16 [public meeting](http://email.prnewswire.com/ls/click?upn=u001.v9xoTZaCB3KDvUFxTt6K9ITfJcLtx-2FOvmuVizoBK57BRgM-2B1taSXU-2F9xU7RxafK6qZ8jcHbxbfYAN-2FxJsiqjA0RcsOC4ziLpqLhkUBv7pYhVrONVnpoPlaujDtb07V8uJDi-2Bk5HuAEFQsDBzFz1kEwbCQvAfyIn46g5eBQsbqfqyh3Dnb0Y8FoGJl1236WRuyaMFCpFiUb1MMfHy4N-2F966l8W8T1J-2FL3zRRDUtB9E6iBlwJwIN52iEizy7tpD-2F3yACsKMUhg56CS0D2DDkPg9z05HIs28JwBnRyKrs93B4k-3DW3y5%5FNiaeg1L98mV4fDNfq75ctkHYKkmcXvQ-2FMI6rl5qIVQYd-2BMDE5rU4mlgOcn0lcLpl-2Bj-2FoEuBcbgi8k4m2OHWZKDfGSfnY4-2FAUiW7oFBP-2FbjZ8TgwkN7wxz1Jdt4BgXAcgThAX-2F7pARRyzIWsSAU74IXPCEy1pdWVEm5IztEesAICX4pYpjuy1GQ9pfYPCoj7jiQTKSOhBA8AKaLv-2FmhyEJTyXQsSDoOgYfC7fhQggOgXFNGcYzoEFOQ19Xc-2B57T2rgsIHkxFOAmv59glLs-2Bdcy2AwEiUiPV3-2BD26d4h8D-2B4QfoA2XM-2F5y4Dya30QeAE84vjjeFQW7ZvOZ72tJKmMQkG0U2OUY2mV8E8y0vQ2Gd3aJ6HKkO-2B3WjDRc4egao-2B6m&ref=fdaweb.com) on “Evaluating the Negative Symptoms of Schizophrenia in Clinical Trials” to discuss approaches to developing drugs to treat the negative symptoms of schizophrenia and disseminate important regulatory considerations for programs designed to evaluate such drugs. The hybrid meeting requires registration for attending in-person, but it is not required for those attending virtually. The meeting will take place at FDA’s White Oak, MD campus (Conference Center).